REGENXBIO Inc (RGNX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Gene Therapysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-16. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 49/100 (MEDIUM), 7.1 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 22.29% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
- Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call
- Regenxbio stock gains on positive gene therapy trial data
- REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
- REGENXBIO to Participate in Upcoming Investor Conferences
- Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome
- REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
- Regenxbio’s RGX-121 Setback Carries A Potential Cash Risk, Warns Clear Street
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Early Intraretinal Fluid Reduction is Linked to Vision Gains in Patients with Diabetic Macular Edema. — Ophthalmol Ther 2026 Sep 22 PMID 42771326
- Neurofilament light chain (NfL) as a surrogate outcome measure for GM2 gangliosidoses. — J Neurol 2026 Jul 17 PMID 42467089
- Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up. — Cardiol Ther 2026 Sep PMID 42384320
- Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid. — J Am Heart Assoc 2026 Jul 7 PMID 42333640
- Optimizing Care for Growth and Puberty in Duchenne Muscular Dystrophy: A Survey of Clinical Practice in the OPTIMIZE DMD Consortium. — Muscle Nerve 2026 Aug PMID 42178495
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for REGENXBIO Inc.
Full RGNX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.